What is Trisalus Life Sciences?
TriSalus Life Sciences is an emerging immuno-oncology company dedicated to developing immunotherapy treatments for liver and pancreatic tumors. Their core innovation lies in novel delivery technologies, specifically the proprietary Pressure-Enabled Drug Delivery infusion system, designed to administer therapeutics intravascularly into visceral organ solid tumors. The company is actively pursuing multiple solid tumor indications with its investigational SD-101 and is working to acquire additional immuno-oncology agents. TriSalus' strategy involves combining these agents with checkpoint inhibitors to reprogram the immunosuppressive cell population within liver and pancreatic tumors, aiming to overcome the inherent immune suppression in the solid tumor microenvironment.
How much funding has Trisalus Life Sciences raised?
Trisalus Life Sciences has raised a total of $122.6M across 8 funding rounds:
Unspecified
$3.7M
Series A
$6.1M
Unspecified
$16.4M
Series B
$18.2M
Series C
$15M
Series D
$12.9M
Debt
$350K
Debt
$50M
Unspecified (2011): $3.7M, investors not publicly disclosed
Series A (2011): $6.1M led by Partisan Management Group and High Country Venture
Unspecified (2013): $16.4M, investors not publicly disclosed
Series B (2013): $18.2M featuring MCG Partners, Partisan Management Group, and High Country Venture
Series C (2015): $15M backed by Tullis Health Investors
Series D (2017): $12.9M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2024): $50M supported by OrbiMed
Key Investors in Trisalus Life Sciences
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various stages of development with a comprehensive understanding of healthcare innovation cycles.
High Country Venture
High Country Venture is a venture capital firm based in Boulder, Colorado, that invests in early-stage companies with scalable, innovative technologies, particularly in the life sciences sector including medical devices and biotechnology.
Tullis Health Investors
Tullis Health Investors is a private equity firm specializing in high-growth, commercial-stage healthcare companies, focusing on medical devices, specialty pharmaceuticals, and biotechnology to build long-term value and enhance global health outcomes.
What's next for Trisalus Life Sciences?
The recent strategic investment in Trisalus Life Sciences signals a strong validation of its therapeutic approach and delivery system. This capital infusion is expected to accelerate the company's clinical development pipeline, potentially enabling further trials for its investigational SD-101 and the integration of newly acquired immuno-oncology agents. The focus on reprogramming the tumor microenvironment in liver and pancreatic cancers positions Trisalus to address significant unmet needs in oncology. Future growth will likely involve expanding its portfolio of therapies and advancing its proprietary delivery system to enhance the efficacy of immunotherapies in challenging solid tumor indications.
See full Trisalus Life Sciences company page
